Adial Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ADIL Adial Pharmaceuticals Inc
OMTK Omnitek Engineering Corp
SH ProShares Short S&P500
NIO NIO Inc
CBIO Catalyst Biosciences Inc
MMM 3M Co
NMHLY NMC Health PLC
HBIO Harvard Bioscience Inc
GNCA Genocea Biosciences Inc
INTU Intuit Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.

Postmarket

Last Trade
Delayed
$2.25
0.0299 (1.35%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.22
Day's Change
-0.03 (-1.33%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.26
Day's Low
2.13
Volume
(Average)
Volume:
568,679

10-day average volume:
624,668
568,679

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.